Altimmune (NASDAQ:ALT) CFO Gregory Weaver Acquires 5,000 Shares of Stock

Altimmune, Inc. (NASDAQ:ALT) CFO Gregory Weaver acquired 5,000 shares of the business’s stock in a transaction that occurred on Friday, March 6th. The stock was bought at an average cost of $3.54 per share, for a total transaction of $17,700.00. Following the completion of the purchase, the chief financial officer directly owned 28,078 shares in the company, valued at $99,396.12. This represents a 21.67% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

Altimmune Stock Up 9.6%

Shares of Altimmune stock opened at $3.88 on Tuesday. The stock has a market capitalization of $437.78 million, a P/E ratio of -3.84 and a beta of 0.13. The company has a quick ratio of 17.18, a current ratio of 17.18 and a debt-to-equity ratio of 0.08. The stock has a 50 day moving average price of $4.49 and a two-hundred day moving average price of $4.29. Altimmune, Inc. has a 12-month low of $2.90 and a 12-month high of $7.73.

Altimmune (NASDAQ:ALT) last released its quarterly earnings results on Thursday, March 5th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.02). Altimmune had a negative net margin of 214,860.98% and a negative return on equity of 54.03%. The firm had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.00 million. Equities analysts expect that Altimmune, Inc. will post -1.35 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. William Blair reaffirmed a “market perform” rating on shares of Altimmune in a research report on Thursday. Barclays began coverage on Altimmune in a research report on Tuesday, January 27th. They set an “overweight” rating and a $20.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Altimmune in a report on Monday, December 29th. B. Riley Financial dropped their price target on Altimmune from $18.00 to $13.00 and set a “buy” rating on the stock in a research report on Friday. Finally, Citigroup reissued a “market outperform” rating on shares of Altimmune in a research report on Wednesday, November 12th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Altimmune has a consensus rating of “Hold” and an average price target of $16.60.

Institutional Investors Weigh In On Altimmune

Institutional investors have recently bought and sold shares of the business. Arax Advisory Partners increased its holdings in Altimmune by 99.7% in the 4th quarter. Arax Advisory Partners now owns 8,165 shares of the company’s stock valued at $29,000 after buying an additional 4,076 shares during the period. SBI Securities Co. Ltd. lifted its holdings in shares of Altimmune by 27.9% during the 4th quarter. SBI Securities Co. Ltd. now owns 8,837 shares of the company’s stock worth $32,000 after acquiring an additional 1,928 shares during the period. Geneos Wealth Management Inc. acquired a new stake in shares of Altimmune during the 1st quarter valued at about $50,000. Victory Capital Management Inc. acquired a new stake in shares of Altimmune during the 3rd quarter valued at about $38,000. Finally, BNP Paribas Financial Markets increased its stake in Altimmune by 108.5% in the second quarter. BNP Paribas Financial Markets now owns 10,095 shares of the company’s stock valued at $39,000 after acquiring an additional 5,253 shares during the period. Institutional investors and hedge funds own 78.05% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.